bioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG

Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.

Rancoderm is a German biotechnology company that develops innovative therapeutic solutions for chronic wounds. Its core focus is DermaPro, a novel active ingredient system designed to treat difficult-to-heal skin wounds such as diabetic foot syndrome and leg ulcers. A subsidiary of bioXXmed AG, Rancoderm is responsible for the research, clinical development and forthcoming market approval of this medical device, which has the potential to significantly improve wound healing outcomes.

Rose Investment- und Beteiligungs, based in Altenstadt, Hesse, is a German stock corporation focused on acquiring stakes in companies in the pharmaceutical, biotechnology and alternative energy sectors. The company also operates solar power plants, finances companies in these sectors and manages their activities.

bioXXmed is a publicly listed German investment company active in biotechnology and medical technology. The company invests in businesses developing innovative therapies and medical devices, particularly for chronic wound care and regenerative diseases. bioXXmed holds stakes in Rancoderm and DermaTools Biotech GmbH, supporting their research, development and regulatory approval processes for new active ingredients and therapeutic concepts.

Oaklins’ team in Germany acted as the lead advisor to bioXXmed and its management throughout the transaction. Given the target’s distressed stage, the process was time-critical, and a strategic buyer was identified within the required timeframe.